KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Share-based Compensation (2016 - 2025)

AbbVie (ABBV) has disclosed Share-based Compensation for 14 consecutive years, with $157.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 4.27% to $157.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $955.0 million, a 4.83% increase, with the full-year FY2025 number at $955.0 million, up 4.83% from a year prior.
  • Share-based Compensation was $157.0 million for Q4 2025 at AbbVie, down from $209.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $410.0 million in Q1 2025 to a low of $107.0 million in Q2 2022.
  • A 5-year average of $198.8 million and a median of $171.5 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: plummeted 32.7% in 2022, then soared 67.29% in 2023.
  • AbbVie's Share-based Compensation stood at $129.0 million in 2021, then grew by 2.33% to $132.0 million in 2022, then decreased by 5.3% to $125.0 million in 2023, then skyrocketed by 31.2% to $164.0 million in 2024, then fell by 4.27% to $157.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Share-based Compensation are $157.0 million (Q4 2025), $209.0 million (Q3 2025), and $179.0 million (Q2 2025).